Can the flu vaccine be administered after taking another medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Flu Vaccine Administration After Taking Jubbonti

The flu vaccine can be safely administered after taking Jubbonti (tezepelumab), as there are no specific contraindications or interactions between these medications. Injectable inactivated influenza vaccines (IIV) can be administered to persons receiving other medications without concern for interactions 1.

Types of Influenza Vaccines and Considerations

There are two main types of influenza vaccines to consider:

  • Inactivated Influenza Vaccines (IIV) can be administered to persons receiving other medications without any special timing considerations 1
  • Live Attenuated Influenza Vaccine (LAIV) requires special consideration with certain medications, but not with biologics like Jubbonti 1

Administration Guidelines

When administering the flu vaccine after Jubbonti:

  • No waiting period is required between Jubbonti administration and receiving an inactivated influenza vaccine 2
  • Separate injection sites should be used if both medications are administered on the same day 2
  • No dose adjustments are needed for either medication 3

Special Considerations

Medication Interactions

  • Unlike influenza antiviral medications (such as oseltamivir, zanamivir, peramivir, or baloxavir) which may interfere with live attenuated influenza vaccines, Jubbonti (tezepelumab) has no known interference with any influenza vaccine formulations 1
  • Jubbonti is a biologic agent that targets thymic stromal lymphopoietin (TSLP) and does not have the same immunosuppressive properties as some other biologics that might affect vaccine response 3

Immunosuppressive Considerations

  • For patients on immunosuppressive medications, the CDC recommends inactivated vaccines rather than live vaccines 1
  • While Jubbonti is a biologic agent, it is not considered immunosuppressive in the same way as medications like rituximab, which would require special timing considerations for vaccination 1

Practical Recommendations

  1. For most patients taking Jubbonti:

    • Proceed with annual influenza vaccination using an inactivated influenza vaccine (IIV) without any special timing considerations 1
    • No need to adjust Jubbonti dosing schedule around vaccination 3
  2. If considering Live Attenuated Influenza Vaccine (LAIV):

    • LAIV can be administered to healthy, non-pregnant persons aged 2-49 years who are not immunocompromised 1
    • There are no specific contraindications for LAIV with Jubbonti, unlike with influenza antiviral medications 1
  3. For optimal vaccine effectiveness:

    • Administer the vaccine at least 2 weeks before the start of influenza season to allow time for antibody development 4
    • Consider the patient's overall health status and any other medications they may be taking 1

Common Pitfalls to Avoid

  • Don't delay influenza vaccination unnecessarily - timely vaccination is important for protection against seasonal influenza 2
  • Don't confuse Jubbonti with immunosuppressive biologics like rituximab that would require special vaccination timing 1, 5
  • Don't administer live vaccines to patients who are severely immunocompromised, though Jubbonti itself is not considered to cause severe immunosuppression 1

In summary, patients taking Jubbonti can safely receive their annual influenza vaccination without any special timing considerations or dose adjustments. The inactivated influenza vaccine is appropriate for all patients, while the live attenuated vaccine may be an option for eligible patients who are not otherwise immunocompromised.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Simultaneous Administration of Pneumonia, Influenza, and COVID-19 Vaccines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Managing a Missed Dose of Tezspire (Tezepelumab)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Influenza: Diagnosis and Treatment.

American family physician, 2019

Guideline

Rheumatoid Arthritis Treatment with Biologic Agents

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.